ES2162871T3 - Derivados oxindoles sustituidos en la posicion 3 de accion biologica, utiles como agentes anti-angiogenicos. - Google Patents

Derivados oxindoles sustituidos en la posicion 3 de accion biologica, utiles como agentes anti-angiogenicos.

Info

Publication number
ES2162871T3
ES2162871T3 ES94931583T ES94931583T ES2162871T3 ES 2162871 T3 ES2162871 T3 ES 2162871T3 ES 94931583 T ES94931583 T ES 94931583T ES 94931583 T ES94931583 T ES 94931583T ES 2162871 T3 ES2162871 T3 ES 2162871T3
Authority
ES
Spain
Prior art keywords
hydrogen
alkyl
halogen
tetralin
isoquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94931583T
Other languages
English (en)
Inventor
Franco Buzzetti
Antonio Longo
Maria Gabriella Brasca
Fabrizio Orzi
Angelo Crugnola
Dario Ballinari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Application granted granted Critical
Publication of ES2162871T3 publication Critical patent/ES2162871T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PRESENTA EL NUEVO USO DE UN COMPUESTO DE LA FORMULA (I) EN LA QUE Y ES UN ANILLO BICICLICO SELECCIONADO DEL NAFTALENO, TETRALINA, QUINOLINA, ISOQUINOLINA E INDOL; N ES CERO O UN ENTERO DE 1 A 3; R{SUB,1} ES HIDROGENO, ALQUILO C{SUB,1}-C{SUB,6} O ALCANOILO C{SUB,2}-C{SUB,6}; R{SUB,2} ES HIDROGENO, HALOGENO, ALQUILO C{SUB,1}-C{SUB,6}, CIANO, CARBOXI, NITRO O NHR, EN DONDE R ES HIDROGENO O ALQUILO C{SUB,1}-C{SUB,6}; R{SUB,3} ES HIDROGENO O ALQUILO C{SUB,1}-C{SUB,6}; R{SUB,4} ES HIDROGENO, HIDROXI, ALCOXI C{SUB,1}-C{SUB,6}, ALCANOILOXI C{SUB,2}-C{SUB,6}, CARBOXI, NITRO O NHR, EN DONDE R ES COMO SE HA DEFINIDO ARRIBA; R{SUB,5}ES HIDROGENO, ALQUILO C1{SUB,1}-C{SUB,6} O HALOGENO; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; Y EN LA QUE CUANDO Y ES NAFTALENO N ES CERO O UN ENTERO DE 1 A 3, MIENTRAS QUE CUANDO Y ES TETRALINA, QUINOLINA, ISOQUINOLINA O INDOL N ES CERO, 1 O 2; Y EN LA QUE CUANDO EL ANILLO BICICLICLO Y ES NAFTALENO, QUINOLINA, ISOQUINOLINA O INDOL, CADA UNO DE LOS SUSTITUYENTESOR{SUB,2}, R{SUB,2} Y OXINDOLILIDENO PUEDEN ESTAR INDEPENDIENTEMENTE EN CUALQUIERA DE LA UNIDADES ARILO O HETEROARILO DE DICHO ANILLO BICICLICO, MIENTRAS QUE SOLO LA UNIDAD DE BENCENO SE SUSTITUYE CUANDO Y ES TETRALINA; Y EN LA QUE CUANDO Y ES NAFTALENO, TETRALINA, QUINOLINA O ISOQUINOLINA, R{SUB,2} ES HIDROGENO, HALOGENO, CIANO O ALQUILO C{SUB,1}C{SUB,6} Y R{SUB,3}, R{SUB,4} Y R{SUB,5} SON HIDROGENO; MIENTRAS QUE CUANDO Y ES INDOL, R{SUB,2} ES HIDROGENO, HALOGENO, ALQUILO C{SUB,1}-C{SUB,6}, CIANO, CARBOXI, NITRO O -NHR, EN DONDE R ES COMO SE HA DEFINIDO ARRIBA, R{SUB,3} ES HIDROGENO O ALQUILO C{SUB,1}-C{SUB,6,}, R{SUB,4} ES HIDROGENO, HIDROXI, ALCOXI C{SUB,1}-C{SUB,6}, ALCANOILOXI C{SUB,2}-C{SUB,6}, CARBOXI, NITRO O -NHR, EN DONDE R ES COMO SE HA DEFINIDO ARRIBA Y R{SUB,5} ES HIDROGENO, HALOGENO O ALQUILO C{SUB,1}-C{SUB,6}; COMO AGENTE ANTIANGIOGENICO.
ES94931583T 1993-12-22 1994-11-08 Derivados oxindoles sustituidos en la posicion 3 de accion biologica, utiles como agentes anti-angiogenicos. Expired - Lifetime ES2162871T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939326136A GB9326136D0 (en) 1993-12-22 1993-12-22 Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents

Publications (1)

Publication Number Publication Date
ES2162871T3 true ES2162871T3 (es) 2002-01-16

Family

ID=10746990

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94931583T Expired - Lifetime ES2162871T3 (es) 1993-12-22 1994-11-08 Derivados oxindoles sustituidos en la posicion 3 de accion biologica, utiles como agentes anti-angiogenicos.

Country Status (17)

Country Link
US (1) US5576330A (es)
EP (1) EP0684820B1 (es)
JP (1) JPH08507089A (es)
KR (1) KR960700707A (es)
AT (1) ATE204168T1 (es)
AU (1) AU676958B2 (es)
CA (1) CA2155098A1 (es)
DE (1) DE69427962T2 (es)
ES (1) ES2162871T3 (es)
GB (1) GB9326136D0 (es)
HU (1) HUT73176A (es)
IL (1) IL112010A (es)
NO (1) NO953146D0 (es)
PL (1) PL310379A1 (es)
TW (1) TW273510B (es)
WO (1) WO1995017181A1 (es)
ZA (1) ZA9410204B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9610964D0 (en) * 1996-05-24 1996-07-31 Pharmacia & Upjohn Spa Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9611797D0 (en) * 1996-06-06 1996-08-07 Pharmacia Spa Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
WO1998024432A2 (en) * 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
WO1999009982A1 (en) 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
ATE276763T1 (de) 1998-07-13 2004-10-15 Univ Texas Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
US6630488B1 (en) 1998-09-21 2003-10-07 Biochem Pharma, Inc. Quinolizinones as integrin inhibitors
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
BR9916327A (pt) * 1998-12-17 2001-09-18 Hoffmann La Roche Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
CN1158283C (zh) 1998-12-17 2004-07-21 霍夫曼-拉罗奇有限公司 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚
EP1149093A1 (en) 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
SI1255752T1 (sl) 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
NZ522074A (en) * 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
JP2003535847A (ja) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
AU2002303892A1 (en) 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
JP2005529080A (ja) * 2002-03-08 2005-09-29 エモリー　ユニバーシティ 腫瘍の増殖および脈管形成のサプレッサとしての新規のクルクミノイド−第ＶＩＩａ因子構築物
EP2357009A1 (en) 2002-07-15 2011-08-17 Board of Regents, The University of Texas System Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
ES2809302T3 (es) 2004-01-22 2021-03-03 Univ Miami Formulaciones de coenzima Q10 para tratar tumores sólidos mediante administración intravenosa
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
ES2572356T3 (es) 2007-11-09 2016-05-31 Peregrine Pharmaceuticals Inc Composiciones de anticuerpos dirigidos contra VEGF y procedimientos
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
EP2633864A1 (en) 2008-07-25 2013-09-04 The Regents of the University of Colorado Clip inhibitors and methods of modulating immune function
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CN102115469A (zh) * 2011-03-21 2011-07-06 浙江大学 吲哚啉-2-酮类衍生物的制备和用途
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP2837626A1 (en) * 2013-08-16 2015-02-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Indolinone derivatives as GRK5 modulators
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3576726A1 (en) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9000950D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa New arylvinylamide derivatives and process for their preparation
GB9000939D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa Improvement in the total synthesis of erbstatin analogs
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
EP0586608A1 (en) * 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
WO1994003427A1 (en) * 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation

Also Published As

Publication number Publication date
NO953146L (no) 1995-08-10
EP0684820A1 (en) 1995-12-06
DE69427962D1 (de) 2001-09-20
IL112010A0 (en) 1995-03-15
HU9502761D0 (en) 1995-11-28
HUT73176A (en) 1996-06-28
KR960700707A (ko) 1996-02-24
AU676958B2 (en) 1997-03-27
US5576330A (en) 1996-11-19
TW273510B (es) 1996-04-01
GB9326136D0 (en) 1994-02-23
DE69427962T2 (de) 2002-04-04
ZA9410204B (en) 1995-11-10
ATE204168T1 (de) 2001-09-15
IL112010A (en) 1998-10-30
EP0684820B1 (en) 2001-08-16
NO953146D0 (no) 1995-08-10
JPH08507089A (ja) 1996-07-30
CA2155098A1 (en) 1995-06-29
AU8061294A (en) 1995-07-10
WO1995017181A1 (en) 1995-06-29
PL310379A1 (en) 1995-12-11

Similar Documents

Publication Publication Date Title
ES2162871T3 (es) Derivados oxindoles sustituidos en la posicion 3 de accion biologica, utiles como agentes anti-angiogenicos.
CA2053253A1 (en) New aryl-and heteroarylethenylene derivatives and process for their preparation
DK151808C (da) Analogifremgangsmaade til fremstilling af oxadiazolylimidazo-oe1,4aa-benzodiazepinderivater
GR3036579T3 (en) 5-arylindole derivatives and their use as serotonin (5-ht 1?) agonists.
DE69528229D1 (en) N-substituierte beta-aryl und beta-heteroaryl-alpha-cyamoacrylamidderivate als tyrosine kinase inhibitoren
HUP9902111A2 (hu) Biciklusos aminok és N-oxidjaik, intermedierjeik, előállításuk és alkalmazásuk, a vegyületeket tartalmazó inszekticid, akaricid és nematocid készítmények
ATE228364T1 (de) Indolalkaloide als antientzündliche wirkstoffe
PT96757A (pt) Processo de preparacao de derivados de indolo e de composicoes farmaceuticas
MX9204194A (es) Los compuestos de 1,2,4-oxadiazolil-fenoxialquilisoxazolas y su uso como agentes antivirales
AU3773397A (en) Method for preparing halogenated 2-amino or 2-acetamido trifluoromethylbenzene derivatives
DK316986A (da) Kemiske forbindelser, som er phosphodiesterase type iii inhibitorer
DE3362723D1 (en) Pyrido-triazoloquinazolines, their preparation and use
ES8102144A2 (es) Procedimiento para la preparacion de derivados de la isoqui-noleina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 684820

Country of ref document: ES